|
|
News Breaks | | | | January 3, 2013 | | 08:04 EDT |  | FRX, WPI | Forest Labs announces additional settlement agreement in BYSTOLIC litigation
Forest Laboratories (FRX) and Forest Laboratories Holdings, Ltd. have entered into a settlement agreement with Glenmark Generics Inc., USA, Glenmark Generics Ltd., and Glenmark Pharmaceuticals Ltd. in patent infringement litigation brought by Forest in response to Glenmark's abbreviated new drug application seeking approval to market generic versions of Forest's BYSTOLIC® tablets. This settlement agreement is in addition to the previously announced BYSTOLIC® patent infringement settlement agreements with Hetero Labs Ltd., Alkem Laboratories, Ltd., Indchemie Health Specialties Pvt. Ltd., and Torrent Pharmaceuticals Ltd. Specifically, under the terms of the settlement agreement and subject to review of the settlement terms by the U.S. Federal Trade Commission, Forest will provide a license to Glenmark that will permit it to launch its generic versions of BYSTOLIC® as of the date that is the later of (a) three calendar months prior to the expiration of U.S. Patent No. 6,545,040, including any extensions and/or pediatric exclusivities or (b) the date Glenmark receives final FDA approval of its ANDA, or earlier in certain circumstances. Similar patent infringement litigation brought by Forest against Amerigen Pharmaceuticals Ltd. and Watson Pharmaceuticals (WPI) and related companies and subsidiaries thereof, remains pending in a multidistrict litigation established in the U.S. District Court for the Northern District of Illinois | |
|
News For FRX;WPI From The Last 14 Days Check below for free stories on FRX;WPI the last two weeks. |
|
|
| May 20, 2013 | | 07:28 EDT |  | FRX | American Thoracic Society to hold a conference
 Subscribe for More Information | | | 07:27 EDT | | FRX | American Psychiatric Association to host annual meeting
Subscribe for More Information | | | May 17, 2013 | | 10:36 EDT | | FRX | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information | | | May 10, 2013 | | 10:00 EDT |  | FRX | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. | | | May 9, 2013 | | 16:34 EDT | | FRX | Forest Labs initiated with an Underperform at BMO Capital
Subscribe for More Information | | | 06:05 EDT | | FRX | Forest Labs and Trevene to co-develop TRV027 for acute heart failure
Subscribe for More Information | |
|
|
|
|
|
|
